The European mesothelioma epidemic by Peto, J et al.
The great majority of mesotheliomas are caused by asbestos, and
the much higher incidence in men indicates that most are due to
occupational rather than environmental exposure. The incidence
continues to rise approximately as the third power of time since
first exposure to asbestos for many decades after exposure has
ceased (Peto et al, 1982), and most patients are men first exposed
30 or more years ago. A country￿s mesothelioma rate is therefore a
quantitative indicator of its population￿s past exposure — mainly
occupational — to asbestos. Mesothelioma is still almost invariably
fatal, so analysis of past cohort mortality patterns should provide a
reasonably reliable prediction of future trends. A recent analysis of
trends in mesothelioma mortality in Britain indicated that the
worst-affected cohorts were born in the late 1940s, and that the
peak incidence for male mesothelioma will be reached around
2020 (Peto et al, 1995). In contrast, the worst-affected American
male generation was born in the late 1920s, the peak will be
reached before the year 2000 and mortality will decline rapidly
thereafter (Price, 1997). The analysis of trends in Britain was
based on the British mesothelioma register, which includes all
deaths for which the word ￿mesothelioma￿ appears on the death
certificate (OPCS/HSE, 1995). For most countries, the only
routinely available national data that correspond reasonably
closely to mesothelioma incidence are death rates for cancer of the
pleura. We have therefore analysed trends in male pleural cancer
mortality for Britain and six other European countries in order to
predict European trends in mesothelioma over the next 30 years.
DATA AND METHODS
Deaths from all causes and from pleural cancer as well as details of
resident populations for all European countries were abstracted
from the World Health Organization (WHO) database (La Vecchia
et al, 1992). Analysis was restricted to countries having a male
population of at least 3 million and complete data from 1970 to
1992 or later. After adding data for 1970—71 for The Netherlands
and since 1991 for Britain and Italy from national sources, the data
were complete up to 1992 for France and The Netherlands, to 1993
for Germany, Italy and Switzerland and to 1994 for Britain. These
six countries together account for 72% of the population of
Western Europe and accounted for 86% of all male pleural cancer
deaths in Western Europe in 1990. Hungary had complete data
from 1970 to 1994 and was also included. Two revisions of the
International Classification of Diseases (ICD) were used during
this period. Pleural cancer was coded 163.0 under the Eighth
Revision and 163 under the Ninth Revision.
Age-specific death rates were analysed in 5-year calendar
periods beginning in 1970—74 and 5-year age groups from 40—44
to 80—84. We chose the lower age limit of 40 partly because
mesothelioma is very rare at younger ages, but also because a
disproportionate number of cases in young people may not be
caused by asbestos (Peto et al, 1981). Age-standardized rates were
based on the world standard population.
Statistical modelling
The effects of age and cohort of birth were estimated by fitting a
log-linear Poisson model to the age-specific death rates for each
5-year calendar period from 1970—74 to 1985—89 using GLIM
(Decarli et al, 1987; Peto et al, 1995). Cohorts were defined
according to their central year of birth. Thus, for example, individ-
uals dying in the quinquennium 1970—74 aged 80—84, who could
have been born in any of the 10 years from 1885 to 1894, were
assigned to the 1890 birth cohort. The results of the analysis are
summarized for each country by predicted age-specific death rates
for men in the 1945 birth cohort, which is the latest cohort for
which data prior to 1990 were available, and the cumulative prob-
ability (up to age 85) of dying from pleural cancer for each birth
The European mesothelioma epidemic
J Peto1,6, A Decarli2,3, C La Vecchia2,4, F Levi5 and E Negri4
1Section of Epidemiology, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK; 2Istituto di Statistica Medica e Biometria, Universitá degli Studi di
Milano, 20133 Milan, Italy; 3Istituto per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; 4Istituto di Ricerche Farmacologiche ‘Mario Negri’, 20157 Milan, Italy;
5Registre Vaudois des tumeurs, Institut Universitaire de Médecine Sociale et Préventive, CHUV-Falaises 1, CH-1011 Lausanne, Switzerland; 6London School of
Hygiene and Tropical Medicine, London WC1E 7HT, UK
Summary Projections for the period 1995–2029 suggest that the number of men dying from mesothelioma in Western Europe each year will
almost double over the next 20 years, from 5000 in 1998 to about 9000 around 2018, and then decline, with a total of about a quarter of a
million deaths over the next 35 years. The highest risk will be suffered by men born around 1945–50, of whom about 1 in 150 will die of
mesothelioma. Asbestos use in Western Europe remained high until 1980, and substantial quantities are still used in several European
countries. These projections are based on the fit of a simple age and birth cohort model to male pleural cancer mortality from 1970 to 1989 for
six countries (Britain, France, Germany, Italy, The Netherlands and Switzerland) which together account for three-quarters of the population
of Western Europe. The model was tested by comparing observed and predicted numbers of deaths for the period 1990–94. The ratio of
mesothelioma to recorded pleural cancer mortality has been 1.6:1 in Britain but was assumed to be 1:1 in other countries.
Keywords: mesothelioma; pleural cancer; mortality trends; Europe
666
British Journal of Cancer (1999) 79(3/4), 666–672
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0105
Received 8 April 1998
Revised 16 June 1998
Accepted 16 June 1998
Correspondence to: J PetoThe European mesothelioma epidemic 667
British Journal of Cancer (1999) 79(3/4), 666–672 © Cancer Research Campaign 1999
cohort. Future populations were calculated by standard actuarial
methods from the 1985—89 population figures, assuming 1985—89
death rates for all causes for each later period and ignoring migra-
tion. Predicted numbers of pleural cancer deaths from 1990 to
2029 were then calculated for each country based on the age-
cohort analysis of the data from 1970 to 1989. The validity of the
model was tested by comparing observed and predicted numbers
of deaths since 1990. Data for this last period were available for
1990—92 for France and The Netherlands, for 1990—93 for
Germany, Italy and Switzerland and for 1990—94 for Britain and
Hungary. Predicted numbers since 1990 were therefore calculated
by interpolation. For example, the central year of birth of French
men aged 50—54 in 1990—92 is 1939, so the cohort parameter
assumed for this cell was 0.8 of the 1940 plus 0.2 of the 1935 birth
cohort parameter estimates. For the purpose of long-term predic-
tion, pleural cancer death rates for the 1950 birth cohort were
assumed to equal those of the 1945 birth cohort. The validity of
this assumption was assessed by comparing observed and
predicted numbers of deaths since 1990 at age 40—44 (Table 2).
The rate for the 1955 birth cohort was assumed to be 50% less, and
mortality in subsequent birth cohorts was not considered.
Between 1985 and 1989, 74% (2886/3916) of British meso-
thelioma deaths were classified as pleural (Health and Safety
Commission, 1997). (A review of mesothelioma deaths between
1986 and 1991 showed that only 55% were actually coded to ICD
163 as the underlying cause (OPCS/HSE 1995), as mention of
another site or cause can take precedence under ICD rules even
when pleural malignancy is mentioned. Fifteen per cent were
coded as lung, 5% as peritoneal, 21% as other or unspecified
cancers and 4% as non-malignant causes). This proportion fell to
62% (3308/5352) in 1990—94 as a result of a change in coding
procedure. Systematic medical enquiries to clarify ambiguous
causes of death ceased in Britain for deaths registered in 1993 or
later (Office for National Statistics, 1996), resulting in a sharp
decrease in the number of mesothelioma deaths for which the
word ￿pleural￿ was added to the death certificate as a result of such
enquiries and a corresponding increase in the number classified as
site not specified, which rose from 255 (24%) in 1992 to 603
(49%) in 1994 (Health and Safety Commission, 1997). For the
purpose of comparing observed and predicted mortality since
1990, predicted numbers of British pleural cancer deaths in
1990—94 were therefore multiplied by 0.84 (0.62/0.74) to allow for
this change (Table 2).
RESULTS
Table 1 shows trends in male age-standardized death certification
rates from pleural cancer in the seven countries. In 1970—74 the
lowest rates were in Britain and Hungary (0.3 per 100 000) and the
highest were in The Netherlands (0.8), France (0.7) and Italy (0.7).
Substantial rises were observed in all countries (from +68% in
Italy to +264% in Britain). The rate in the period since 1990 was
0.7 in Hungary, 2.4 in The Netherlands and between 1.1 and 1.4 in
other countries.
The results of the age-cohort analysis for each country are
summarized in Figure 1, which shows predicted age-specific rates
for men born in 1945 and the predicted lifetime probability of
death from pleural cancer for each birth cohort from 1890 to 1945.
Lifetime risks, which are corrected for total mortality, were calcu-
lated assuming 1985—89 death rates for all causes for each birth
cohort, and within each country are directly proportional to the
estimated cohort parameters. The fit of the age-cohort analysis was
adequate in each country, the goodness of fit Chi-squared (16 d.f.)
ranging from 9.3 (P = 0.9) for France to 25.9 (P = 0.06) for Italy,
with observed and fitted numbers differing significantly (Poisson
P < 0.05) in only two of the total of 252 age-period cells. The
highest risk was suffered by the most recent (1945) birth cohort in
most countries. Predicted lifetime probabilities of dying from
pleural cancer for men born in 1945 were 0.58% for France, 0.31%
for Germany, 0.35% for Italy, 1.39% for The Netherlands, 0.44%
for Switzerland, 0.69% for Britain and 0.10% for Hungary.
Table 1 Trends in age-standardizeda death rates per 100 000 men from
pleural cancer in seven European countries, 1970–94
Period Per cent
change
Country 1970–74 1975–79 1980–84 1985–89 1990–94 in rates
Britain 0.33 0.52 0.69 1.05 1.20 +264
France 0.68 0.87 1.08 1.36 1.42 +109
Germany 0.52 0.60 0.79 0.93 1.14 +129
Italy 0.74 0.75 0.98 1.14 1.24 +68
Netherlands 0.84 1.13 1.71 2.02 2.39 +184
Switzerland 0.63 0.69 0.97 1.17 1.35 +114
Hungary 0.32 0.39 0.49 0.52 0.70 +118
aWorld standard population.
Table 2 Observed and predicted male pleural cancer deaths at age 40–44 and at age 45–84 since 1990
Number of deaths Goodness of fit of
age + cohort model
Country Period Age 40–44 Age 45–84 to data for 1970–89
Observed Predicted Observed Predicted c2 (16 d.f.) (P)
Britain 1990–94 46 46.5a 2302 2407a 14.2 (0.58)
France 1990–92 39 45.4 1596 1724 9.3 (0.90)
Germany 1990–93 46 48.2 2457 2324 18.7 (0.28)
Italy 1990–93 39 46.1 2192 2079 25.9 (0.06)
Netherlands 1990–92 11 13.5 669 695 24.4 (0.08)
Switzerland 1990–93 4 5.8 252 250 16.4 (0.43)
Hungary 1990–94 14 5.4 204 207 14.8 (0.54)
All countries 199 211 9672 9686
aPredicted numbers for Britain in 1990–94 have been multiplied by 0.84 to allow for the change in coding procedure described under Data and methods.668 J Peto et al
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Mortality in men born in 1950 or later
The only data on men in the 1950 birth cohort are deaths at ages
40—44 occurring since 1990. These observed numbers are
compared in Table 2 against those predicted under the assumption
that the 1945 and 1950 birth cohort rates are equal. The correspon-
dence is close, both overall (199 deaths, 211 predicted) and for
each country except Hungary (14 observed, 5.4 predicted; P <
0.01). For the purpose of predicting future numbers of deaths, it
was therefore assumed that the 1945 and 1950 birth cohorts will
suffer identical rates. The data in Table 2 suggest that this is
approximately true both overall and for the six Western European
countries. Future numbers of deaths were not calculated for
Hungary. The risk to Hungarian men born in 1950 is probably
considerably greater than to those born in 1945, but with only 14
deaths in the 1950 birth cohort no reliable projection is possible.
The 1955 birth cohort in each country was assumed to suffer
50% of the 1950 cohort rate, which was the estimate derived from
the British mesothelioma register data (Peto et al, 1995). Mortality
in subsequent birth cohorts was not considered. This inevitably
arbitrary assumption for men born around 1955 and the exclusion
of deaths in men born since 1955 have little effect on predicted
numbers of deaths up to the year 2020, but subsequent mortality
will depend increasingly on the unknown risk to men born since
1955 for whom no data are yet available.
Observed and predicted mortality since 1990
A projection of future mortality based on past trends may be exag-
gerated, perhaps severely, by increasing diagnostic awareness of
mesothelioma over the last 20 years. We therefore excluded the
most recent (1990—94) data from our age-cohort analysis to
provide an independent test of our predictions based on the
1970—89 trends. The right-hand part of Table 2 shows observed
and predicted numbers of pleural cancer deaths since 1990 in men
aged 45—84 for each country. The correspondence is reasonably
close (within ± 7%) in each country, and the overall observed and
predicted numbers are almost identical (9672 observed, 9686
predicted).
Figure 2 gives the observed numbers of pleural cancer deaths
per year in the six Western European countries up to 1989, and
predicted numbers up to 2029. For most countries the predicted
peak occurs in 2015—19, with about 1750 deaths per year in
Britain, 1550 in France, 1370 in Germany, 940 in Italy, 930 in The
Netherlands and 160 in Switzerland. These figures are two to three
times higher than those in 1990—94. The full impact of the
epidemic is summarized in Table 3, which shows for each country
the lifetime risk suffered by men born around 1945—50, the
number of deaths per year at the peak of the epidemic in 2015—19
and the total number of pleural cancer deaths over the 35 years
from 1995 to 2029. The predicted total for the six Western
European countries is 190 000 deaths.
Relationship between pleural cancer and mesothelioma
rates
There may be substantial differences between countries in the
proportion of deaths from other causes which are incorrectly coded
as pleural cancer (ICD 163) and in the proportion of mesothelioma
deaths that are coded as pleural cancer. In Britain, 55% (2447/4443)
of male mesothelioma deaths in the period 1986—91 were coded
163, and 89% (2447/2745) of death certificates coded 163 included
the word mesothelioma and hence were recorded in the mesothe-
lioma register (OPCS/HSE, 1995). Past trends in British pleural
cancer rates therefore correspond fairly closely to trends in mesothe-
lioma mortality, the latter being about 162% (0.89/0.55) of the
pleural cancer death rate. In France, however, only 70% of a recent
sample of male deaths coded to ICD 163 were found on review to be
definite, probable or possible mesotheliomas (57% definite or prob-
able, 13% possible). The remaining 30% were attributable to other
cancers. In a separate study by the same authors, 75% of male
pleural mesothelioma deaths in France were coded 163, suggesting a
ratio of pleural mesothelioma to pleural cancer of 0.93 (0.70/0.75)
(Brochard et al, 1995). The primary site is peritoneal or undeter-
mined in a substantial proportion of mesotheliomas, however, so the
British figure for the proportion of all mesotheliomas that are coded
163 (55%) may be more appropriate. If so, the overall male
mesothelioma death rate in France would be about 127% (0.70/0.55)
of the pleural cancer mortality rate, implying a current (1998) total
of about 1000 male mesothelioma deaths per year in France, and an
eventual peak of about 2000.
The observation that 30% of recent male deaths in France coded
163 are not mesotheliomas compared with 11% in Britain may also
explain why the overall French pleural cancer rate has exceeded
the British rate by a roughly constant amount since 1970 (Table 1).
If the number of deaths misclassified as pleural cancer each year
has remained roughly constant since 1970, the French age-
standardized rates in each period should be reduced by about 20%
of the recent French rate, i.e. by about 0.3 per 100 000 per annum,
to make them comparable to the British rates. Table 1 shows that
this adjustment would make the overall French and British pleural
cancer rates almost identical in each period since 1970. This crude
Table 3 Lifetime pleural cancer risk for men born in 1945–1950 and predicted numbers of pleural cancer deaths in men born in 1955 or earlier
Lifetime risk of pleural Number of deaths per year Total number of deaths
cancer death (%) in men in 2015–19 1995–2029
Country born 1945–50
Britain 0.69 1750 48 100
France 0.58 1550 45 000
Germany 0.31 1370 38 900
Italy 0.35 940 28 300
Netherlands 1.39 930 25 300
Switzerland 0.44 160 4 600
Total 6700 190 200The European mesothelioma epidemic 669
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correction cannot be applied to age-specific rates, however, as
lung cancer, the disease most commonly miscoded as pleural
cancer, has exhibited large changes in incidence in Western
Europe over recent decades, increasing at older ages and declining
at younger ages due to historical changes in cigarette consumption
and tar levels (Peto et al, 1994).
There is thus considerable uncertainty in the relationship
between recorded pleural cancer and true mesothelioma mortality
rates. The apparently marked differences between Britain and
France in the overall death rate in 1970—74 and in the rate of
increase since 1970 are at least partly due to differences in death
certification procedures, but no detailed data on the relationship
between pleural cancer and mesothelioma rates are available for
other countries. Overall mortality trends in Germany, Italy and
Switzerland have been similar to those in France, with age-
adjusted rates in the range 0.5—0.7 in 1970—74 increasing to
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Figure 1 Results of the age and birth cohort analysis of male pleural cancer mortality in seven European countries. Predicted pleural cancer death rate for
men born in 1945 and lifetime probability of dying from pleural cancer (to age 85, allowing for other causes of death) for each birth cohort from 1890 to 1945670 J Peto et al
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1.1—1.4 in 1990—94. In the absence of data on the relationship
between pleural cancer and mesothelioma mortality comparable to
those described above for Britain and France, we have therefore
assumed that the ratio of mesothelioma to pleural cancer in the
other Western European countries is similar to that in France. For
the purpose of predicting mesothelioma trends we have assumed
that this ratio is approximately unity, but it could be considerably
higher.
DISCUSSION
The extraordinarily high mesothelioma incidence throughout
Western Europe in men born around 1945—50 reflects the extent of
asbestos use in the 1960s and 1970s at the beginning of their
working lives. Annual raw asbestos imports to European Union
countries peaked in the early to mid 1970s and remained above
800 000 tonnes per year until 1980, falling to about 100 000
tonnes by 1993 (European Commission, 1996). Increasingly strin-
gent exposure limits were enforced in the manufacture of asbestos-
containing products over this period, but exposure to users of such
materials, particularly in the building industry, remained virtually
uncontrolled in many countries. Chrysotile asbestos products are
still widely used in several European countries, and maintenance
or demolition work on older buildings may result in substantial
exposure to amphiboles as well as to chrysotile. We have not
included men born after 1955 in our projections, but the effects of
asbestos exposure during the 1980s and 1990s, although not yet
apparent, may prove considerable.
Many European countries introduced legislation to ban the use of
crocidolite during the 1970s, and an EC Directive banning the sale
and use of all amphiboles has been in force since 1993. An expert
committee of the WHO International Programme on Chemical
Safety concluded that chrysotile should not be used in construction
materials (International Programme on Chemical Safety, 1998).
Nine European countries (Denmark, Finland, France, Germany,
Italy, The Netherlands, Norway, Sweden and Switzerland) have
already banned almost all uses of asbestos of any type; and the
British Health and Safety Commission has recently proposed a ban.
Most epidemiologists agree that all forms of asbestos can cause both
lung cancer and mesothelioma, but there is considerable disagree-
ment on the contribution of chrysotile to overall mesothelioma
incidence. In a recent commentary, Cullen (1998) concluded that
chrysotile, although less dangerous than amosite and much less so
than crocidolite, is probably the main cause of mesothelioma world-
wide in view of its far wider use, while McDonald and her
colleagues (1997) argued that very few mesotheliomas are caused
by pure chrysotile. Decisive evidence remains elusive for several
reasons. Few workers have been exposed only to chrysotile, most
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historical exposure measurements were of particles rather than
fibres, and the interpretation of lung burden studies is complicated
by the rapid pulmonary clearance of chrysotile. The controversy has
focused on the Quebec chrysotile miners and millers (Liddell et al,
1997; McDonald et al, 1997). The ratio of mesothelioma to excess
lung cancer was about 1:4, but the authors attributed most of the 38
mesotheliomas to contamination with tremolite, and concluded that
exposure below 300 million particles per cubic foot—years, which
was stated to be equivalent to 10 years at 80 fibre ml—1, was virtually
innocuous. The dose-specific lung cancer risk in this cohort was
very much lower than among chrysotile textile workers, who
suffered a much higher lung cancer risk than the miners but a low
mesothelioma risk (Dement et al, 1983a,b; McDonald et al, 1983). It
is, however, not clear that the enormous particle counts in the
Quebec mines constitute a useful measure of exposure to fibres of
relevant size (Doll and Peto, 1985). The quantitative effects on risk
for each disease of increasing the fibre length from 10 mm to
100 mm or the diameter from 0.02 mm to 0.2 mm are not known, and
the large differences in dose-specific lung cancer risk and in the ratio
of mesothelioma to excess lung cancer between cohorts exposed
mainly to chrysotile may be at least partly due to differences in fibre
dimension.
In the absence of a specific ICD code for mesothelioma, we were
obliged to base our analyses on the death rate from pleural cancer
(ICD 163), an unsatisfactory surrogate that includes a substantial
number of lung cancer deaths and excludes mesotheliomas that are
not specifically described as pleural on the death certificate. The fit
of the age cohort trends up to 1989 and the agreement between
observed and predicted numbers since 1990 suggest that ICD 163
has been used fairly consistently in coding deaths over the past 25
years, but there are no satisfactory data on the ratio between pleural
cancer and mesothelioma mortality except in Britain. France is
the only other country for which any relevant data have been
published, and the French surveys were too small to provide precise
estimates (178 pleural mesothelioma deaths and a separate survey
of approximately 150 deaths coded 163) and did not cover
mesotheliomas in which the site of origin was peritoneal or
unknown (Brochard et al, 1995). It is thus not clear whether the
ratio of mesothelioma to pleural cancer in France and in other
European countries is close to unity or considerably higher.
A substantial proportion of recent pleural cancer deaths are not
mesotheliomas (11% in Britain and about 30% in France), but this
proportion will decline as the number of mesotheliomas increases.
The majority of these miscoded deaths are attributable to lung
cancer, which is now declining among men (although not among
women) in many Western European countries (Peto et al, 1994).
Allowance for this would increase our predictions of future
mesothelioma mortality, but in the absence of age-specific data on
miscoding in each country the appropriate adjustment is not
possible. It is unfortunate that the evolution of the epidemic of
asbestos-induced mesothelioma, which far exceeds the combined
effects of all other known industrial carcinogens, cannot be
adequately monitored.
Future mesothelioma trends in Western Europe
The consistency of the age-cohort pattern in each country suggests
that our prediction that the annual number of pleural cancer deaths
in Western Europe will more than double between 1990—94 and
2015—19 is reasonably reliable. The prediction for Britain (after
adjustment for the ratio between recorded pleural cancer and true
mesothelioma rates) is close to that derived from the British
mesothelioma register (Peto et al, 1995). Lifetime risks in Britain
are particularly low for men born around 1900 and higher than in
any country other than The Netherlands for men born since 1940.
The pattern in Hungary is atypical, with relatively low risks to men
born in 1945 or earlier but evidence of a substantially higher risk
to men born in 1950. Cohort trends are generally similar in the
remaining four countries, the lifetime risk increasing from about
0.1% for men born in 1905 to between 0.3% and 0.6% for men
born in 1945. Data for 1990 in the WHO database show wide vari-
ation in other European countries. Recent pleural cancer rates are
similar to those presented here in Scandinavia but are about four
times less in the remainder of Western Europe.
The predicted number of male pleural cancer deaths for the six
Western European countries is 3700 per year for 1998, 6700 per
year for 2015—19 and a total of 190 000 between 1995 and 2029
(Table 3). The ratio of male mesothelioma to recorded pleural
cancer is about 1.6:1 in Britain and appears to be at least 1:1 in
France, and the cohort trends suggest that French death coding
practice may be more typical of other European countries.
Assuming a ratio of 1:1 for all countries other than Britain would
imply a total of 220 000 male mesothelioma deaths between 1995
and 2029 in the six countries. In 1990 these countries accounted
for almost three-quarters of the population and accounted for 86%
of all male pleural cancer deaths in Western Europe. The number
of male mesothelioma deaths in the whole of Western Europe is
thus likely to be about 250 000 over the next 30—35 years, and the
number of men dying of mesothelioma each year in Western
Europe will almost double over the next 20 years, from about 5000
in 1998 to about 9000 in 2018. These estimates suggest that about
1 in 150 of all Western European men born around 1945—50 will
die of mesothelioma, and the risk to the occupational groups at
highest risk, notably building and engineering workers, must be
very much higher.
Our long-term predictions depend crucially on the assumption
that the pattern of age-specific rates seen in the past will persist for
the next 30 years. In addition to the possible effects of trends in
diagnostic completeness, the shape of the age distribution may
have been altered by the large reduction in asbestos use that
occurred in many countries around 1980. The level of exposure of
men born since about 1935 was probably greatly reduced in
middle age or earlier, which may eventually cause some flattening
of their age-incidence curve compared with that of earlier birth
cohorts and thus reduce their eventual risk. The pleural cancer
mortality data up to 1994 show no sign of such a change (Table 2),
and the numbers of male deaths from 1992 to 1994 in the British
mesothelioma register were close both overall and at each age to
those predicted by Peto et al (1995) based on the trends up to 1991
(Hodgson et al 1997). The total number of deaths in the register in
1995 was also very close to that predicted, but the 1995 and provi-
sional 1996 data suggest a deficit among men born since 1935 (J T
Hodgson, personal communication). Pleural cancer mortality
trends in Europe will be disrupted by the introduction of the 10th
revision of the ICD, which includes a specific code for mesothe-
lioma, and the most reliable test of our longer term projections, at
least for Britain, will be provided by future data from the British
mesothelioma register.
The ratio of excess lung cancer to mesothelioma in historical
cohort studies of heavily exposed asbestos workers has usually
been three or higher (Health Effects Institute, 1991) but evidence
from two sources suggests that among less heavily exposed users672 J Peto et al
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of asbestos products the excess of lung cancer may be similar to or
even less than the mesothelioma risk. All traceable workers
covered by the 1969 UK Asbestos Regulations or the Asbestos
(Licensing) Regulations have been followed up through the British
Health and Safety Executive￿s Asbestos Survey (OPCS/HSE,
1995). Among men in the survey there were 729 lung cancer
deaths compared with 533 expected. This excess of lung cancer
(observed minus expected = 196) was almost equal to the number
of mesothelioma deaths (175). British proportional mortality ratios
(PMRs) for mesothelioma and lung cancer suggest an even lower
ratio of excess lung cancer to mesothelioma in the construction
industry. The three building-related occupational groups with the
highest PMRs for mesothelioma were plumbers and gas fitters
(PMR 443), carpenters (PMR 366) and electricians (PMR 291).
The PMRs for lung cancer for these three groups were 107, 94 and
87 respectively (OPCS/HSE, 1995). These surprisingly low ratios
may reflect different dose—response relationships related to expo-
sure level or fibre size for these cancers, differences in the long-
term pattern of risk many years after exposure has ceased or a
disproportionate contribution of amphiboles, particularly crocido-
lite. Whatever the explanation, it appears that the number of lung
cancers caused by asbestos is unlikely to exceed the number of
mesotheliomas and may be substantially less.
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